Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

NCT07566494 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Disease, Hemolytic Anemia

Interventions

DRUG: VAS-101

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)